| Literature DB >> 30428880 |
Kassoum Kayentao1, Lia S Florey2, Jules Mihigo3, Abdoul Doumbia4, Aliou Diallo3, Diakalia Koné4, Ogobara Doumbo5, Erin Eckert2.
Abstract
BACKGROUND: Major investments have been made since 2001, with intensification of malaria control interventions after 2006. Interventions included free distribution of insecticide-treated nets (ITN) to pregnant women and children under 5 years old, the introduction of artemisinin combination therapy (ACT) for malaria treatment, and indoor residual spraying of insecticides. Funders include the Government of Mali, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the US President's Malaria Initiative.Entities:
Keywords: Evaluation; Impact; Intervention; Malaria; Mali; Under-five mortality
Mesh:
Year: 2018 PMID: 30428880 PMCID: PMC6236933 DOI: 10.1186/s12936-018-2573-1
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Timeline illustrating funding, evaluation periods and timing of implementation of malaria policies and interventions, Mali, 2000–2012. Between 2001 and 2012, the Government of Mali (GOM) and its international development partners invested heavily in a series of malaria control policies and strategies. These included: (1) distribution of ITNs (by social marketing, free to high risk populations, and finally via universal national campaign); (2) IPTp (beginning in 2003); (3) use of ACT (launched in 2006) and a test-and-treat policy (implemented in 2010); (4) IRS (launched in 2008 in 2 districts). The greatest investment came after 2006 from sources including GOM, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and PMI
Fig. 2Conceptual framework for an adequacy and plausibility assessment supporting Mali malaria impact evaluation [5]. This evaluation is based on the premise that in high-burden countries, malaria constitutes a sizeable percentage of child mortality, such that improvements in the coverage of malaria control interventions (ITN, IRS, IPTp, case management) should result in a subsequent decline in ACCM. This ‘plausibility argument’ is the current standard for measuring the impact of scale up of malaria control over the past decade. Using ACCM as the primary outcome indicator ensures a robust measure that encompasses both direct and indirect malaria-related mortality. As the association between malaria control interventions and ACCM is mediated by malaria-specific outcomes, this evaluation also includes analyses of several measures of malaria-associated morbidity. Malaria infections and severe anaemia are both outcomes on the causal pathway between malaria control intervention coverage and ACCM. Available morbidity data include prevalence of severe anaemia and of malaria parasitaemia in children. Trends in potential contextual factors influencing the changes in ACCM were also explored
Trends of malaria intervention coverage indicators, Mali, 2000–2015
| Interventions | 2001 | 2006 | 2010 | 2012–2013 | 2015 | Changea | p£ |
|---|---|---|---|---|---|---|---|
| Nets | |||||||
| Household ownership | n/a | 40.5 (37.3–42.7) | 62.9 (60.3–65.4) | 70.6 (69.4–71.8) | n/a | 30.1 | < 0.0001 |
| ITNs | |||||||
| Household ownership ≥1 | n/a | 49.4 (46.6–52.2) | 87.2 (84.1–89.7) | 84.4 (83.1–85.6) | 93.0 (91.8–94.1) | 43.6 | < 0.0001 |
| Use (children < 5 yrs) | n/a | 26.4 (24.0–29.0) | 72.6 (68.2–76.7) | 69.0 (67.2–70.7) | 71.2 (68.9–69.6) | 44.8 | < 0.0001 |
| Use (pregnant women) | n/a | 27.6 (23.4–32.2) | 73.2 (69.6–76.5) | 77.9 (74.4–81.0) | 50.3 | < 0.0001 | |
| Use (all persons) | n/a | 20.7 (18.9–22.5) | 56.9 (53.8–59.9) | 60.5 (59.0–62.0) | 63.9 (62.0–65.8) | 43.2 | < 0.001 |
| IPTp during last pregnancy | |||||||
| 2+ doses | n/a | 10.1 (8.6–12.0) | NA | 28.5 (26.3–30.9) | 37.8 (34.5–41.1) | 27.7 | < 0.0001 |
| Recommended first-line malaria treatment | |||||||
| 92.4* (90.0–94.3) 1049 | 5.5b (3.6–8.3) | 23.3c (15.8–32.9) | 19.0c (13.4–26.3) | 28.9c (23.0–35.8) | 5.6 | 0.0171 | |
* Chloroquine used as first-line therapy in 2001
£ P value of Chi squared for the two time points indicating the changes above
aAbsolute change from 2006 to 2015, except for recommended first-line malaria treatment where 2010 was the starting point
bSulfadoxine-pyrimethamine used in 2006
cArtemisinin combination therapy used in 2010, 2012–2013, and 2015
Trends in all-cause mortality (per 1000 live births) among 0–59 months of age in Mali, 2001, 2006, and 2012, by background characteristics
| Factors | 2001 | 2006 | 2012 | Changea | Changeb |
|---|---|---|---|---|---|
| Age in months | |||||
| 0–59 | 224.8 (213.3–236.2) | 192.3 (180.8–203.6) | 95.1 (87.8–102.3) | − 14.5 | − 50.5 |
| 6–23 | 79.1 (71.6–86.5) | 66.6 (59.3–73.9) | 18.6 (15.4–21.8) | − 15.8 | − 72.1 |
| 24–59 | 83.3 (74.7–91.8) | 70.4 (61.4–79.4) | 31.9 27.6–36.2) | − 15.5 | − 54.7 |
| Gender | |||||
| Male | 230. 2 (214.8–245.4) | 192.8 (179.2–206.1) | 108.5 (98.5–118.4) | − 16.2 | − 43.7 |
| Female | 219.3 (204.4–233.9) | 191.8 (173.5–209.7) | 80.8 (71.6–89.9) | − 12.5 | − 57.9 |
| Residence | |||||
| Urban | 179.9 (156.2–202.9) | 132.8 (105.8–159.1) | 59.2 (47.6–70.6) | − 26.2 | − 55.4 |
| Rural | 238.2 (225.1–251.2) | 213.4 (201.4–225.2) | 103.2 (94.6–111.7) | − 10.4 | − 51.6 |
| Endemicity | |||||
| Moderate | NA | 130.7 (110.1–150.8) | 60.3 (46.4–74.0) | NA | − 53.9 |
| High | NA | 204.5 (191.5–217.4) | 101.7 (93.4–110.0) | NA | − 50.3 |
| Regions | |||||
| Kayes | 241.3 (216.5–265.2) | 164.9 (138.4–190.6) | 92.8 (75.3–109.9) | − 31.7 | − 43.7 |
| Koulikoro | 218.0 (193.5–241.8) | 210.8 (187.1–233.8) | 86.5 (70.0–102.8) | − 3.3 | − 59.0 |
| Sikasso | 223.5 (195.4–250.6) | 213.0 (194.4–231.2) | 109.9 (91.3–128.1) | − 4.7 | − 48.4 |
| Segou | 250.6 (221.2–278.9) | 228.6 (203.9–252.7) | 102.2 (85.2–119.0) | − 8.8 | − 55.3 |
| Mopti (limited areas) | 260.6 (227.7–292.4) | 189.3 (140.1–235.7) | 102.8 (81.9–123.2) | − 27.4 | − 45.7 |
| Bamako | 129.8 (109.1–150.0) | 99.0 (81.1–116.6) | 54.6 (40.8–68.2) | − 23.7 | − 44.8 |
NA non-applicable because of absence of data
aRelative change from 2001 to 2006
bRelative change from 2006 to 2012
Fig. 3Mortality per 1000 live births from Demographic Health Surveys and routine data, Mali. a Mortality rates from DHSs (2001, 2006, 2012–2013); b all-cause mortality according to routine data from health information system from 2003 to 2012
Prevalence of Plasmodium falciparum carriage among children under 5 years old in Mali, 2010–2015
| Characteristics | 2010 | 2012–2013 | 2015 | Changea | p-value≠ | Changeb | p-value≠≠ |
|---|---|---|---|---|---|---|---|
| Overall | |||||||
| 38.6 (32.6–45.0) | 51.6 (48.5–54.8) | 35.8 (31.7–40.2) | 13 | < 0.0001 | − 2.7 | 0.0360 | |
| Age categories (years) | |||||||
| 6–11 | 15.9 (10.0–24.2) | 41.4 (36.0–47.1) | 23.6 (18.4–29.8) | 25.5 | < 0.0001 | 7.7 | 0.0295 |
| 12–23 | 31.0 (24.5–38.5) | 46.8 (42.7–50.9) | 28.5 (24.5–33.0) | 15.8 | < 0.0001 | − 2.5 | 0.3438 |
| 24–35 | 42.4 (34.1–51.1) | 50.9 (46.5–55.2) | 37.9 (33.2–42.8) | 8.5 | 0.0041 | − 4.5 | 0.1165 |
| 36–47 | 43.8 (35.5–52.5) | 55.0 (50.6–59.2) | 39.0 (34.0–44.2) | 11.2 | 0.0002 | − 4.8 | 0.1041 |
| 48–59 | 47.2 (38.9–55.7) | 58.0 (53.7–62.1) | 43.0 (37.2–48.9) | 10.8 | 0.0004 | − 4.2 | 0.1670 |
| Place of residence | |||||||
| Urban | 4.5 (1.9–10.4) | 16.8 (13.5–20.6) | 13.1 (9.5–17.7) | 12.3 | < 0.0001 | 8.6 | < 0.0001 |
| Rural | 46.6 (39.7–53.6) | 59.5 (55.9–62.9) | 41.2 (36.3–46.2) | 12.9 | < 0.0001 | − 5.4 | < 0.0001 |
| Regions | |||||||
| Kayes | 27.1 (15.0–43.9) | 36.9 (29.7–44.7) | 27.4 (20.3–35.9) | 9.8 | 0.0110 | 0.3 | 0.9127 |
| Koulikoro | 40.4 (27.7–54.4) | 50.2 (41.7–58.8) | 34.8 (25.9–44.8) | 9.8 | 0.0018 | − 5.6 | 0.0594 |
| Sikasso | 58.5 (47.1–69.1) | 62.1 (54.9–68.9) | 41.6 (34.6–48.9) | 3.6 | 0.3275 | − 16.9 | < 0.0001 |
| Segou | 41.6 (27.0–57.9) | 55.7 (49.9–61.3) | 36.7 (28.2–46.1) | 14.1 | 0.0002 | − 4.9 | 0.0764 |
| Moptic | 50.2 (36.7–63.7) | 70.6 (65.4–75.4) | 59.8 (46.8–71.5) | 20.4 | < 0.0001 | 9.6 | 0.0075 |
| Bamako | 2.1 (0.3–14.4) | 9.9 (7.4–13.0) | 6.0 (3.9–9.1) | 7.8 | 0.0010 | 3.9 | 0.0354 |
aPercent absolute change from 2010 to 2012
bPercent absolute change from 2010 to 2015
cStudy was conducted in selected areas of the region of Mopti which were retained for the overall analysis
≠p-value of Chi squared comparing proportions of 2010 and 2012
≠≠p-value of Chi squared for linear trend in proportions across the three surveys
Prevalence of severe anaemia among children under 5 years old in Mali, 2010–2015
| Characteristics | 2006 | 2010 | 2012–2013 | 2015 | Changea | p-value≠ |
|---|---|---|---|---|---|---|
| Overall | 22.5 (20.0–25.1) | 26.3 (22.5–30.5) | 20.6 (18.9–22.4) | 19.9 (17.4–22.6) | − 2.6 | < 0.0001 |
| Age categories (years) | ||||||
| 6–23 | 31.8 (28.2–35.6) | 33.0 (27.4–39.1) | 25.2 (22.6–28.0) | 23.1 (20.5–26.0) | − 8.7 | < 0.0001 |
| 24–59 | 17.7 (15.3–20.4) | 23.1 (19.3–27.5) | 18.5 (16.5–20.6) | 18.4 (15.7–21.3) | 0.7 | 0.0018 |
| Endemicity | ||||||
| Moderate | 21.2 (15.6–28.1) | 15.1 (15.6–28.1) | 12.5 (9.5–16.2) | 11.6 (9.3–14.4) | − 9.6 | < 0.0001 |
| High | 22.9 (10.1–25.8) | 28.3 (24.0–33.1) | 22.0 (20.1–24.1) | 23.2 (20.1–26.5) | 0.3 | 0.00004 |
| Place of residence | ||||||
| Urban | 11.1 (8.1–15.0) | 9.7 (7.1–13.1) | 8.4 (6.7–10.6) | 7.7 (6.4–9.3) | − 3.4 | 0.0470 |
| Rural | 26.7 (24.1–29.5) | 30.2 (25.8–35.0) | 23.3 (21.4–25.5) | 22.7 (19.9–25.9) | − 4.0 | < 0.0001 |
| Regions | ||||||
| Kayes | 22.6 (16.1–30.9) | 31.8 (22.4–43.0) | 18.9 (15.4–22.9) | 19.9 (15.6–24.4) | − 3.4 | 0.0004 |
| Koulikoro | 25.1 (20.7–30.1) | 21.3 (14.7–29.8) | 20.4 (14.4–25.1) | 19.8 (15.8–24.6) | − 4.0 | 0.0464 |
| Sikasso | 27.0 (22.2–32.3) | 34.6 (27.9–42.0) | 21.1 (17.6–25.0) | 19.4 (15.7–23.7) | − 2.7 | < 0.0001 |
| Segou | 25.6 (21.4–30.3) | 28.7 (19.3–40.3) | 20.5 (16.7–25.0) | 20.3 (16.7–24.4) | − 5.3 | 0.0005 |
| Moptib | 15.8 (8.3–28.1) | 31.0 (22.4–41.1) | 30.1 (25.1–35.6) | 29.5 (19.6–41.8) | 13.7 | < 0.0001 |
| Bamako | 11.5 (8.4–15.6) | 7.4 (4.9–11.1) | 8.3 (6.2–11.0) | 7.4 (5.9–9.4) | − 4.1 | 0.1021 |
aPercent absolute change from the first survey to the last survey
bStudy was conducted in selected areas of the region of Mopti which were retained for the overall analysis
≠p-value of Chi squared for linear trend in proportions across the surveys
Fig. 4Trend of malaria interventions coverage, malaria morbidity (2001–2015), and all-cause mortality in under five (2001–2012), Mali. Declines seen in ACCM were consistent with the timeframe of scale up of malaria control interventions. There is a steady decline in child mortality from 1997 to 2001 onwards, which was more substantial between 2002–2006 and 2008–2012 than in the first half of the evaluation period. The more recent time period corresponds to the period in which malaria interventions (ITNs were distributed nationally and first-line malaria treatment changed to ACT) were scaled up
Prevalence of contextual factors influencing all-cause mortality over time in Mali, 2001 versus 2012–2013
| Factors | 2001 | 2006 | 2012–2013 | Changea | p£ |
|---|---|---|---|---|---|
| Socio-economic | |||||
| Household with improved water source | 43,0 (39–47.1) | 57.5 (53.6–61.3) | 66.0 (62.5–69.3) | 23 | < 0.0001 |
| Households with improved toilets | 6.7 (5.3–8.4) | 10.2 (8.7–11.8) | 17.9 (15.8–20.2) | 11.2 | < 0.0001 |
| Household with modern floor material | 19.8 (19.9–23.1) | 27.2 (23.5–31.2) | 28.4 (25.7–31.2) | 8.6 | < 0.0001 |
| Household with electricity | 11.6 (9.6–14.0) | 17.8 (15.3–20.5) | 25.6 (22.9–28.8) | 14 | < 0.0001 |
| Maternal and reproductive | |||||
| ANC visits 4+ | 31.0 (28.1–34.0) | 63.9 (61.1–66.7) | 41.2 (38.7–43.8) | 10.2 | < 0.0001 |
| Delivery at health centre | 24.4 (21.4–27.7) | 47.7 (43.7–51.8) | 55.0 (51.5–58.5) | 30.6 | < 0.0001 |
| Delivery by qualified staff | 25.5 (22.0–29.3) | 51.7 (47.9–55.5) | 40.1 (36.7–43.5) | 14.6 | < 0.0001 |
| Last pregnancy protected against NNT (at least 2 doses of NNT) | 32.9 (30.4–35.6) | 48.7 (45.7–51.8) | 36.6 (34.3–38.8) | 3.7 | < 0.0001 |
| Vitamin A postnatal supplementation | 18.8 (16.7–21.0) 7528 | 42.2 (39.3–45.2) 7944 | 50.2 (47.6–52.8) 6773 | 31.4 | < 0.0001 |
| Nutrition in children | |||||
| Vitamin A supplementation | 41.4 (38.4–44.5) | 74.1 (71.4–76.6) | 59.8 (57.0–62.4) | 18.4 | < 0.0001 |
| Stunting | 42.2 (40.3–44.0) | 37.6 (35.9–39.4) | 38.3 (36.2–40.4) | − 3.9 | < 0.0001 |
| Underweight | 28.6 (26.7–30.5) | 26.6 (25.0–27.9) | 25.5 (23.6–27.4) | − 3.1 | < 0.001 |
| Emaciation | 12.0 (10.8–13.4) | 14.8 (13.9–15.9) | 12.7 (11.1–14.4) | 0.7 | < 0.0001 |
| Low birth weight | 3.3 (2.7–4.0) | 3.9 (3.4–4.6) | 4.7 (4.0–5.5) | 1.4 | < 0.0001 |
| Immunization coverage | |||||
| BCG | 70.4 (67.0–73.6) | 78.1 (74.5–81.3) | 83.3 (80.8–86.1) | 12.9 | < 0.0001 |
| DPT3 | 41.1 (36.9–45.5) | 69.2 (65.4–72.7) | 63.1 (59.7–66.3) | 22.0 | < 0.0001 |
| Polio3 | 41.3 (37.4–45.2) | 63.6 (60.1–67.1) | 50.0 (46.5–53.6) | 8.7 | < 0.0001 |
| Measles | 50.2 (46.6–53.7) | 63.6 (65.1–73.9) | 71.7 (68.7–74.5) | 21.5 | < 0.0001 |
| Total coverage | 30.0 (26.5–33.8) | 49.6 (45.8–53.5) | 38.9 (35.5–42.4) | 8.9 | < 0.0001 |
| Morbidity (past 2 weeks) | |||||
| Prevalence of diarrhoea | 17.4 (16.1–18.8) | 13.9 (12.7–15.1) | 8.6 (7.7–9.6) | − 8.8 | < 0.0001 |
| Prevalence of ARI | 9.6 (8.6–10.7) | 5.9 (5.2–6.8) | 3.2 (2.7–3.8) | − 6.4 | < 0.0001 |
ANC antenatal clinic, NNT neonatal tetanus toxoid, BCG Bacillus Calmette-Guérin, DPT diphteria pertusis tetanus, ARI acute respiratory infection
aPercent absolute change from 2001 to 2012–2013
£p-value of Chi squared for linear trend in proportions across the three surveys